Avid Bioservices, Inc.


Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) with over 30 years of experience in biologics development, manufacturing, and regulatory compliance. They focus on transforming the CDMO experience with expertise, world-class facilities, and personalized processes to help bring high-quality, lifesaving drugs to market. Recently, they have been acquired by GHO Capital Partners and Ampersand Capital Partners, and they operate state-of-the-art facilities including a mammalian protein CGMP Drug Substance Line 3. The company actively participates in industry conferences and events such as BPI West, ASC BioT, BIO 2025, and others, showcasing their commitment to innovation and industry leadership.

Industries

biotechnology
health-care
medical

Nr. of Employees

large (251-1000)

Avid Bioservices, Inc.

Tustin, California, United States, North America


Products

Mammalian Protein Development & Manufacturing Services

Provides end-to-end solutions for biologics development from early stages to commercial-scale production.

Viral Vector Development & Manufacturing Services

Specializes in the design, optimization, and scalable production of viral vectors for gene therapy and vaccine applications.

Mammalian Protein Drug Substance Development & Manufacturing

Offers development, transfer-in, optimization, and scale-up of processes suitable for CGMP manufacturing.

Mammalian Protein Process Development

Supports research and development needs, process and analytical development, technical transfer, and optimization.

Mammalian Protein CGMP Manufacturing

Provides manufacturing from early-stage development to large-scale commercialization.

Mammalian Protein Analytical Services

Offers experience in transferring, developing, qualifying, and validating client assays.


Services

CGMP contract manufacturing (mammalian protein drug substance)

Clinical and commercial GMP manufacturing of therapeutic proteins and antibodies with large-scale single-use bioreactor capacity and GMP lot release.

Mammalian protein process development

Integrated upstream and downstream development including cell culture optimization, purification development, DoE-based characterization, and pilot production for preclinical material.

Analytical services for development and commercial release

Analytical assay development, method transfer, qualification and validation, biophysical characterization, impurity testing, stability programs, and GMP lot release testing.

Biologics quality and regulatory compliance support

Quality systems and regulatory support to maintain compliance with global regulators, readiness for inspections, and support for multi-market approvals.

Industry engagement and partnership outreach

In-person representation at industry conferences and trade shows to support business development, partner introductions, and stakeholder outreach within the biopharma ecosystem.

Expertise Areas

  • Clinical and commercial biologics manufacturing
  • Upstream and downstream process development
  • Analytical method development and QC testing
  • Regulatory compliance and inspection readiness
  • Show More (5)

Key Technologies

  • Single-use bioreactor systems
  • Fed-batch and perfusion cell culture
  • Tangential flow filtration (TFF) / UF-DF
  • Chromatography (affinity, ion exchange, HIC, SEC)
  • Show More (9)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.